First Patient Enrolled in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study
- Objectives of KIDCARES10 Study (KIg10 in peDiatric subjects: effiCacy, sAfety and phaRmacokinEticS of a 10% IG) a phase III, open-label, prospective, multi-center study are to assess the efficacy, safety, and pharmacokinetics of a 10 percent intravenous immunoglobulin (IVIG) in pediatric patients aged 2 to 17 years and affected by primary immunodeficiency disease (PI)
- Primary efficacy endpoint of KIDCARES10 is incidence rate of acute serious bacterial infections from day 1 to week 51/52
- Primary safety endpoint of KIDCARES10 is safety in the overall study population from day 1 to week 51/52
- Secondary endpoints of KIDCARES10 include clinical, laboratory, pharmacokinetic, and health-related quality of life (HRQoL) measures
Tia, the modern medical home for women, and
CommonSpirit Health, the nation s largest nonprofit health system, today announced an innovative, first-of-its-kind partnership to create a new front door to healthcare for women. The deal enables the two healthcare leaders to launch Tia-branded women s health clinics together that will provide comprehensive, blended virtual and in-person care – with plans for the first clinic in Phoenix where CommonSpirit operates multiple Dignity Health medical centers.
The CommonSpirit relationship is Tia s first major partnership with a national health system. The joint venture clinics will combine a multitude of services and practitioners into a one-stop shop for women that fuses gynecological care and primary care. Tia will provide its distinctive care model, staffing and technology infrastructure, while CommonSpirit will connect Tia to patients, health plan partners, and hospital and specialty care access.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary
RADR
® artificial intelligence ( A.I. ) platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lantern s drug candidate LP-184 in the area of brain tumors, and specifically in
Atypical
Rhabdoid
Tumors ( ATRT ), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children. As we enriched our
RADR
® A.I. platform for additional cancer indications, we began to discover common molecular pathways that drive response to our drug candidate, LP-184, across multiple additional CNS cancers, stated Panna Sharma, President and CEO of Lantern Pharma. Chief among these newly identified CNS cancers was ATRT, an ultra-rare and fast-growing cancerous tumor of the brain tha
Science 37® and Xperiome™ Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Using Science 37 s decentralized clinical trial model, the partnership offers Xperiome s research-ready, rare disease patients more study opportunities with less burden.
News provided by
Share this article
Share this article
LOS ANGELES, March 11, 2021 /PRNewswire/ Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperiome, a global rare disease healthtech company. The partnership further strengthens Science 37 s capabilities to bring research directly to patients, both by easing the patient burden and enabling treating physicians the opportunity to advance research as an investigator. Science 37 will leverage Xperiome s insights from Raremark, its data-driven knowledge bank powered by patients, including a specialized matching engine to connect research-ready members to clinical and real-world study op
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
News provided by
Share this article
Share this article
SUZHOU, China and ROCKVILLE, Md., March 10, 2021 /PRNewswire/ Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company s five novel drug candidates have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, and have already been published in the meeting s official website. This year s AACR annual meeting will be held in a virtual format on April 27-28 and June 22-24.